Zhang Jia-Ying, Zhu Lei, Yang Hong-Kuan, Chen Fang
First Clinical Medical College,Zhejiang Chinese Medicine University,Hangzhou 310053,China.
Department of Lung Function,First Affiliated Hospital,Zhejiang Chinese Medicine University,Hangzhou 310006,China.
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2018 Jun 28;40(3):411-414. doi: 10.3881/j.issn.1000-503X.2018.03.020.
The past few years have witnessed rapid advances in the immunotherapies for non-small-cell lung cancer (NSCLC). CIMAvax-EGF is a therapeutic vaccine against lung cancer independently developed by Cuba. It can exert its anti-tumor effect by forming epidermal growth factor (EGF) antibodies to block the binding of EGF to EGF receptor. So far stage both phases Ⅱ and Ⅲ trials have proved its effectiveness and long-term safety,and phases Ⅲ and Ⅳ trials are underway. A deeper understanding of the role of CIMAvax-EGF in NSCLC will accelerate the application of immunotherapy. This article summarizes the recent advances of CIMAvax-EGF R&D and its application in treating NSCLC.
过去几年见证了非小细胞肺癌（NSCLC）免疫疗法的快速进展。CIMAvax-EGF是古巴自主研发的一种抗肺癌治疗性疫苗。它可通过形成表皮生长因子（EGF）抗体来阻断EGF与EGF受体的结合，从而发挥抗肿瘤作用。到目前为止，Ⅱ期和Ⅲ期试验均已证明其有效性和长期安全性，Ⅲ期和Ⅳ期试验正在进行中。对CIMAvax-EGF在NSCLC中作用的更深入了解将加速免疫疗法的应用。本文总结了CIMAvax-EGF研发及其在治疗NSCLC中的应用的最新进展。
